Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1,173.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,539 shares of the company's stock after purchasing an additional 80,664 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Recursion Pharmaceuticals were worth $611,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. San Luis Wealth Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter worth approximately $69,000. Finally, Vontobel Holding Ltd. purchased a new position in shares of Recursion Pharmaceuticals during the third quarter worth approximately $70,000. Institutional investors own 89.06% of the company's stock.

Analyst Upgrades and Downgrades

RXRX has been the topic of several analyst reports. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, July 11th. Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC dropped their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $9.40.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the sale, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Christopher Gibson sold 30,000 shares of the firm's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares of the company's stock, valued at approximately $5,387,039.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the transaction, the director now directly owns 7,077,560 shares of the company's stock, valued at approximately $47,561,203.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 213,129 shares of company stock valued at $1,398,937. 15.75% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded up $0.08 during mid-day trading on Friday, reaching $6.40. The company's stock had a trading volume of 3,630,489 shares, compared to its average volume of 3,978,813. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.03 and a 12-month high of $15.74. The firm's fifty day moving average price is $6.63 and its two-hundred day moving average price is $7.65. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.80 billion, a P/E ratio of -3.95 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million for the quarter, compared to analysts' expectations of $11.96 million. During the same period in the previous year, the company earned ($0.38) EPS. Recursion Pharmaceuticals's revenue for the quarter was up 30.9% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.